FDA Clearance Tracker · P160037-S005
BD Onclarity HPV Assay/BD COR System
Last checked: Nov 20, 2026Latest source record: Aug 24, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Aug 24, 2021
Approved
Time to decision
588 days
Received Jan 14, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P160037-S005
- Device name
- BD Onclarity HPV Assay/BD COR System
- Applicant
- Becton, Dickinson and Company
- Applicant location
- Sparks, MD
- Received
- Jan 14, 2020
- Decided
- Aug 24, 2021
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P160037
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for use of the BD Onclarity HPV Assay on the BD COR (PX/GX) instrument system.
Source documents
Other decisions for Becton, Dickinson and Company
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K252344 · Decided Oct 16, 2026 · 445 days after receipt
Device type: Tubes, Vials, Systems, Serum Separators, Blood Collection (JKA) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.